Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 6.63 Billion | USD 11.30 Billion | 6.1% | 2023 |
According to the report published by Zion Market Research, the global Neuromodulation Market size was valued at USD 6.63 Billion in 2023 and is predicted to reach USD 11.30 Billion by the end of 2032. The market is expected to grow with a CAGR of 6.1% during the forecast period. The report analyzes the global Neuromodulation Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Neuromodulation industry.
Neuromodulation is the technology that alters or modulates the activity of the nerve by delivering pharmaceutical or electrical agents directly to a target area. Neuromodulation treatments and devices are life changing as they affect every area of the body and treat almost every symptom or disease right from tremors to headaches or urinary incontinence to spinal cord damage. For the next decade, neuromodulation is considered a major growing industry owing to its broad therapeutic scope and ongoing improvements in biotechnology.
The global neuromodulation market is growing at a speedy rate. An increase in prevalence of neurological disorders, a wide range of neuromodulation applications, and growing awareness of neurodegenerative disorders are some of the crucial factors that are fostering the growth of the global market. The most common indication of neuromodulation is most frequently in the context of chronic pain relief. However, there are numerous applications of neuromodulation such as spinal cord stimulation for ischemic disorders, sacral nerve stimulation for pelvic disorders & incontinence, and deep brain stimulation (DBS) treatment for Parkinson's disease. In addition to this, in case of a cochlear implant restoring hearing, response is stimulated by neuromodulation devices in a deaf patient.
All such factors in combination with the development of technology and increase in adoption of neuromodulation therapies are escalating the growth of the global neuromodulation market. Moreover, growing demand for non-invasive procedures for the treatment of diseases and growing geriatric population are also the factors that are propelling the growth of the global market. In addition to this, the enhancement of regulatory processes for developers by the regulatory bodies will further spur the growth of the market. Furthermore, innovations in the devices and treatment may offer several opportunities for the growth of the global neuromodulation market over the forecast period. However, the dearth of skilled professionals may impede the growth of the global neuromodulation market.
Surgical interventions are required by neuromodulation, but during the Covid-19 pandemic, the government shifted the healthcare care workers towards the treatment of covid-19 patients and postponed elective procedures and surgeries. The institutes are been hampered financially due to postponing of the procedures. The sales of neuromodulation devices also declined during the pandemic period. All such factors resulted in the slow growth of the market in the pandemic situation.
The global neuromodulation market is divided into technology, application, and region.
Based on the technology, the global neuromodulation market is bifurcated into external neuromodulation (non-invasive) and internal neuromodulation.
The application segment is classified into Parkinson's disease, pain management, dystonia, depression, epilepsy, tremor, and other applications.
Report Attributes | Report Details |
---|---|
Report Name | Neuromodulation Market |
Market Size in 2023 | USD 6.63 Billion |
Market Forecast in 2032 | USD 11.30 Billion |
Growth Rate | CAGR of 6.1% |
Number of Pages | 193 |
Key Companies Covered | Synapse Biomedical, Inc., LivaNova, Abbott, Boston Scientific Corporation, Medtronic, BioControl Medical, Neuronetics, NeuroPace, NeuroSigma, and Nevro Corporation |
Segments Covered | By technology, By application and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is estimated to hold the largest share in the global neuromodulation market during the forecast period. This is primarily due to the increase in the prevalence of neurological disorders, growing geriatric population demanding non-invasive treatment for pain management, and increase in the adoption of neuromodulation therapies owing to its wide applications. In addition to this, presence of major players in the US is equally contributing to the growth of the market in North America. Europe is estimated to grow at a healthy rate. This is attributed to the increase in investment for the development of neuromodulation therapies. Asia Pacific is expected to grow rapidly and register the fastest growth during the forecast period. An increase in research and rise in neurological disorders are the factors that are fueling the growth of the market in this region.
The global neuromodulation market is highly competitive. Key players are majorly focusing on
product launches to strengthen their presence in the global market.
By Technology Type
By Application Type
FrequentlyAsked Questions
An increase in prevalence of neurological disorders, a wide range of neuromodulation applications, and growing awareness of neurodegenerative disorders are some of the crucial factors that are fostering the growth of the global market. Furthermore, innovations in the devices and treatment may offer several opportunities for the growth of the global neuromodulation market over the forecast period.
Synapse Biomedical, Inc., LivaNova, Abbott, Boston Scientific Corporation, Medtronic, BioControl Medical, Neuronetics, NeuroPace, NeuroSigma, and Nevro Corporation are some of the major players that are operating in the global market.
North America is estimated to hold the largest share in the global neuromodulation market during the forecast period. This is primarily due to the increase in the prevalence of neurological disorders, growing geriatric population demanding non-invasive treatment for pain management, and increase in the adoption of neuromodulation therapies owing to its wide applications. In addition to this, presence of major players in the US is equally contributing to the growth of the market in North America.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed